Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Only 1 Number Mattered in Arena Pharmaceuticals' Q3 Results -- and It Was Big

By Keith Speights - Nov 8, 2019 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Hint: This number won't be found on the biotech's top or bottom lines.

Some biotech stocks might be struggling in 2019, but not Arena Pharmaceuticals ( ARNA -6.81% ). Its share price is up over 20% so far this year. However, that's a lot less than this summer when Arena's shares were up more than 60%.

Arena announced its third-quarter results after the market closed on Thursday. Don't expect the biotech's news to kick off a dramatic rebound, but a major slide isn't likely, either. There was really only one number that mattered in Arena's Q3 results -- and it was a big one.

Lab worker holding up a pill with chemical symbols surrounding it

Image Source: Getty Images.

By the numbers

Arena's top line went in the wrong direction in the third quarter. Revenue fell 61% year over year, to $1.4 million. Analysts were expecting that the company's revenue for Q3 quarter would be close to $2.06 million.

The company reported a net loss of $72.9 million, or $1.46 per share, based on generally accepted accounting principles (GAAP). This compared to a net loss of $34.3 million, or $0.70 per share, in the same period in 2018. The Q3 net loss was also worse than the consensus analyst estimate of a net loss of $1.32 per share.

Arena ended the third quarter with cash, cash equivalents, and short-term investments of $1.2 billion. The company had $686.9 million on hand as of Dec. 31, 2018.

Behind the numbers

Does anyone really care that Arena's revenue dropped and its net loss worsened? Not really. 

The biotech's only source for revenue right now is collaboration and royalty revenue. In the third quarter, Arena received $811,000 from royalties and $539,000 from collaboration revenue. 

But Arena's wider net loss was less a result of its lower year-over-year revenue and more from its increased spending. The company reported that its operating costs more than doubled from the prior-year period, to $80.7 million. Research and development costs totaled $60.3 million, while general and administrative costs were $20.4 million -- both roughly twice the levels from the same quarter last year.

The only number that really mattered in Arena's Q3 update was its cash position. Arena continues to enjoy a nice cash stockpile resulting from its deal with United Therapeutics to license pulmonary arterial hypertension (PAH) drug ralinepag.

Looking ahead

What's important for Arena going forward is its pipeline progress. Expect some movement on that front in the near future. 

CEO Amit Munshi said that Arena is still on course to begin a phase 2/3 study of etrasimod in treating Crohn's disease and file for FDA approval to begin a phase 1 study of experimental heart-failure drug APD418 this year. The company also has several clinical studies in progress, including its late-stage study evaluating etrasimod in treating ulcerative colitis, a phase 2 study evaluating etrasimod in treating atopic dermatitis, and a phase 2 study of olorinab in treating abdominal pain associated with irritable bowel syndrome (IBS).

The best news of all for the company coming out of the third quarter is that it should have plenty of cash to fund all of these clinical programs for a while to come.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arena Pharmaceuticals, Inc. Stock Quote
Arena Pharmaceuticals, Inc.
$49.55 (-6.81%) $-3.62
United Therapeutics Corporation Stock Quote
United Therapeutics Corporation
$185.99 (-1.74%) $-3.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.